Department of Medicine, University of Pittsburgh Medical Center, USA.
Int Immunopharmacol. 2013 Apr;15(4):752-5. doi: 10.1016/j.intimp.2013.02.021. Epub 2013 Mar 15.
Intravenous immunoglobulin (IVIG) replacement has been shown to decrease the risk of post-transplant infections secondary to hypogammaglobulinemia, however the use of subcutaneous immunoglobulin (SCIG) in this population has not been reported. A retrospective analysis of the efficacy and tolerability of subcutaneous immunoglobulin replacement on 10 lung-transplant recipients was performed. All 10 patients demonstrated an increase in IgG levels at three months that was sustained at 6-12 months with SCIG replacement therapy, with the majority (70%) tolerating infusion without complications. The results of this study suggest that subcutaneous IgG replacement therapy is a well tolerated alternative to IVIG.
静脉注射免疫球蛋白（IVIG）替代疗法已被证明可降低因低丙种球蛋白血症导致的移植后感染风险，然而，在该人群中使用皮下免疫球蛋白（SCIG）尚未见报道。对 10 例肺移植受者进行了皮下免疫球蛋白替代疗法的疗效和耐受性的回顾性分析。所有 10 例患者在三个月时 IgG 水平均升高，并且在 6-12 个月时 SCIG 替代治疗仍持续升高，大多数患者（70%）耐受输注，无并发症。本研究结果表明，皮下 IgG 替代疗法是 IVIG 的一种耐受良好的替代疗法。
